首页|Deciphering the molecular mechanisms of Simiaowan in the treatment of hyperuricemia:in vivo and in silico approaches

Deciphering the molecular mechanisms of Simiaowan in the treatment of hyperuricemia:in vivo and in silico approaches

扫码查看
Background:Simiaowan(SMW),a well-known traditional Chinese medicine,has been employed to treat hyperuricemia(HUA)and gout for centuries.However,the bioactive components and underlying mechanisms have not been elucidated.The objective of this study was to identify the active components and potential mechanisms of SMW by integrating pharmacological experimentation,serum pharmacochemistry,network pharmacology and molecular docking.Methods:HUA rats modelling by high-fat/high-sugar diet and potassium oxonate/adenine oral administration were used to evaluate the pharmacodynamic effects of SMW.UPLC-Q-Exactive-MS/MS was employed to detect the bioactive components present in SMW-containing serum.Network pharmacology and molecular docking were utilized to elucidate the potential targets and underlying mechanisms.Results:SMW effectively ameliorated HUA rats via the inhibition of uric acid(UA)production,promotion of UA excretion,improvement of lipid and glucose metabolic abnormalities,antioxidant,anti-inflammatory and anti-insulin resistance effects.A total of 73 compounds detected in SMW-containing serum were identified as potential active components,with alkaloids,flavonoids,organic acids,and terpenoids emerging as the primary active ingredients.Totally 203 corresponding targets were obtained as SMW anti-HUA/gout targets,which mainly participated in apoptosis,insulin resistance,TNF,PI3K-Akt,HIF-1,NF-κB,MAPK,IL-17 and TLR signaling pathways.Molecular docking indicated that active compounds(e.g.berberine,phellodendrine,quercetin,formononetin,ferulic acid)had superior binding abilities to the key targets(e.g.solute carrier family 22 member 12(URAT1),solute carrier family 22 member 6(OAT1),ATP-binding cassette sub-family G member 2(ABCG2),solute carrier family 2,facilitated glucose transporter member 9(GLUT9),xanthine dehydrogenase/oxidase(XDH),transcription factor p65(RELA),toll-like receptor 4(TLR4),prostaglandin G/H synthase 2(PTGS2),caspase-3(CASP3),insulin(INS)).Conclusion:SMW exerted regulatory influence over the disease network of HUA and gout through a multiplicity of components,targets,and pathways.Alkaloids,flavonoids,organic acids,and terpenoids were the primary active components,exerting anti-HUA/gout effects via antioxidant,anti-inflammatory,anti-insulin resistance,anti-apoptosis,inhibition of UA production,and promotion of UA excretion.This study revealed the active components and molecular mechanisms of SMW,providing insights into the development of natural products derived from SMW.

hyperuricemianetwork pharmacologyserum pharmacochemistrySimiaowanUPLC-Q-Exactive-MS/MS

Yong-Chang Zeng、Jun-Hong Wu、Dan-Dan Xu、Kang He、Chang-Qing Liu、Li-Fei Song、Zheng-Zhi Wu、Qian-Qian Jiang、Shao-Yu Liang

展开 >

Department of Neurology,The First Affiliated Hospital of Shenzhen University,Shenzhen 518020,China

Pharmaceutical Department,The Affiliated TCM Hospital of Guangzhou Medical University,Guangzhou 510000,China

School of Pharmacy,Guizhou University of Traditional Chinese Medicine,Guiyang 550025,China

Guangzhou Zeli Medical Technology Co.,Ltd.,Guangzhou 510700,China

展开 >

2025

传统医学研究(英文版)
天津市金匮灵兰科技有限公司

传统医学研究(英文版)

ISSN:2413-3973
年,卷(期):2025.10(2)